Results: 51-75/1697
Authors:
O'Mahony, L
Feeney, M
O'Halloran, S
Murphy, L
Kiely, B
Fitzgibbon, J
Lee, G
O'Sullivan, G
Shanahan, F
Collins, JK
Citation: L. O'Mahony et al., Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice, ALIM PHARM, 15(8), 2001, pp. 1219-1225
Authors:
Plattner, V
Leray, V
Leclair, MD
Aube, AC
Cherbut, C
Galmiche, JP
Citation: V. Plattner et al., Interleukin-8 increases acetylcholine response of rat intestinal segments, ALIM PHARM, 15(8), 2001, pp. 1227-1232
Authors:
Nogi, K
Haruma, K
Taniguchi, H
Yomota, E
Okajima, M
Hananoki, M
Hata, J
Kusunoki, H
Onoda, Y
Citation: K. Nogi et al., Duodenogastric reflux following cholecystectomy in the dog: role of antroduodenal motor function, ALIM PHARM, 15(8), 2001, pp. 1233-1238
Authors:
Cook, TA
Brading, AF
Mortensen, NJM
Citation: Ta. Cook et al., Review article: the pharmacology of the internal anal sphincter and new treatments of ano-rectal disorders T., ALIM PHARM, 15(7), 2001, pp. 887-898
Authors:
Selvasekar, CR
Birbeck, N
Mcmillan, T
Wainwright, M
Walker, SJ
Citation: Cr. Selvasekar et al., Review article: photodynamic therapy and the alimentary tract, ALIM PHARM, 15(7), 2001, pp. 899-915
Authors:
Gisbert, JP
Gonzalez, L
Calvet, X
Roque, M
Gabriel, R
Pajares, JM
Citation: Jp. Gisbert et al., Proton pump inhibitors versus H-2-antagonists: a meta-anaiysis of their efficacy in treating bleeding peptic ulcer, ALIM PHARM, 15(7), 2001, pp. 917-926
Authors:
Vakil, NB
Shaker, R
Johnson, DA
Kovacs, T
Baerg, RD
Hwang, C
D'Amico, D
Hamelin, B
Citation: Nb. Vakil et al., The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety, ALIM PHARM, 15(7), 2001, pp. 927-935
Authors:
Appel-Dingemanse, A
Horowitz, A
Campestrini, J
Osborne, S
McLeod, J
Citation: A. Appel-dingemanse et al., The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young, ALIM PHARM, 15(7), 2001, pp. 937-944
Authors:
Soni, A
Sonnenberg, A
Citation: A. Soni et A. Sonnenberg, Healthcare resource utilization in the management of oesophageal adenocarcinoma, ALIM PHARM, 15(7), 2001, pp. 945-951
Authors:
Di Marco, V
Vaccaro, A
Ferraro, D
Alaimo, G
Rodolico, V
Parisi, P
Peralta, S
Di Stefano, R
Almasio, PL
Craxi, A
Citation: V. Di Marco et al., High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C, ALIM PHARM, 15(7), 2001, pp. 953-958
Authors:
Longstreth, GF
Hawkey, CJ
Mayer, EA
Jones, RH
Naesdal, J
Wilson, IK
Peacock, RA
Wiklund, IK
Citation: Gf. Longstreth et al., Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials, ALIM PHARM, 15(7), 2001, pp. 959-964
Authors:
Testoni, PA
Bagnolo, F
Andriulli, A
Bernasconi, G
Crotta, S
Lella, F
Lomazzi, A
Minoli, G
Natale, C
Prada, A
Toti, GL
Zambelli, A
Citation: Pa. Testoni et al., Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial, ALIM PHARM, 15(7), 2001, pp. 965-972
Authors:
Kelly, P
Musuku, J
Kafwembe, E
Libby, G
Zulu, I
Murphy, J
Farthing, MJG
Citation: P. Kelly et al., Impaired bioavailability of vitamin A in adults and children with persistent diarrhoea in Zambia, ALIM PHARM, 15(7), 2001, pp. 973-979
Authors:
Shaw, MJ
Beebe, TJ
Adlis, SA
Talley, NJ
Citation: Mj. Shaw et al., Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients, ALIM PHARM, 15(7), 2001, pp. 981-987
Authors:
Konturek, PC
Konturek, SJ
Sulekova, Z
Meixner, H
Bielanski, W
Starzynska, T
Karczewska, E
Marlicz, K
Stachura, J
Hahn, EG
Citation: Pc. Konturek et al., Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer, ALIM PHARM, 15(7), 2001, pp. 989-999
Authors:
Bazzoli, F
Palli, D
Zagari, RM
Festi, D
Pozzato, P
Nicolini, G
Masala, G
Fossi, S
Ricciardiello, L
Panuccio, D
Roda, E
Citation: F. Bazzoli et al., The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by C-13-urea breath test and associated factors, ALIM PHARM, 15(7), 2001, pp. 1001-1007
Authors:
You, JHS
Lee, KKC
Ho, SSS
Sung, JJY
Kung, NNS
Yung, M
Lee, C
Yee, GC
Citation: Jhs. You et al., Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong, ALIM PHARM, 15(7), 2001, pp. 1009-1015
Authors:
Perri, F
Villani, MR
Quitadamo, M
Annese, V
Niro, GA
Andriulli, A
Citation: F. Perri et al., Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadrupletherapy?, ALIM PHARM, 15(7), 2001, pp. 1017-1022
Authors:
Perri, F
Villani, MR
Festa, V
Quitadamo, M
Andriulli, A
Citation: F. Perri et al., Predictors of failure of Helicobacter pylori eradication with the standard'Maastricht triple therapy', ALIM PHARM, 15(7), 2001, pp. 1023-1029
Authors:
Pilotto, A
Franceschi, M
Leandro, G
Bozzola, L
Rassu, M
Soffiati, G
Di Mario, F
Valerio, G
Citation: A. Pilotto et al., Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole, ALIM PHARM, 15(7), 2001, pp. 1031-1036
Authors:
Tepes, B
Krizman, I
Gorensek, M
Gubina, M
Orel, I
Citation: B. Tepes et al., Is a one-week course of triple anti-Helicobacter pylori therapy sufficientto control active duodenal ulcer?, ALIM PHARM, 15(7), 2001, pp. 1037-1045
Authors:
Hurenkamp, GJB
Grundmeijer, HGLM
Van der Ende, A
Tytgat, GNJ
Assendelft, WJJ
Van der Hulst, RWM
Citation: Gjb. Hurenkamp et al., Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study, ALIM PHARM, 15(7), 2001, pp. 1047-1054
Authors:
Laheij, RJF
Jansen, JBMJ
Verbeek, ALM
Verheugt, FWA
Citation: Rjf. Laheij et al., Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease, ALIM PHARM, 15(7), 2001, pp. 1055-1059
Authors:
Calvet, X
Garcia, N
Gene, E
Campo, R
Brullet, E
Sanfeliu, I
Citation: X. Calvet et al., Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment, ALIM PHARM, 15(7), 2001, pp. 1061-1065
Authors:
Calvet, X
Gene, E
Lopez, T
Gisbert, JP
Citation: X. Calvet et al., What is the optimal length of proton pump inhibitor-based triple therapiesfor H-pylori? A cost-effectiveness analysis, ALIM PHARM, 15(7), 2001, pp. 1067-1076